Addex Reclaims GABAB Rights, Funds Runway Into Q4 2027

Addex Therapeutics regained full GABAB PAM rights from Indivior and raised $2.8 million to fund operations into Q4 2027 while reporting a stable $3.4 million net loss.

Addex Therapeutics Ltd (ADXN) has regained control of its GABAB PAM program and secured financing to fund operations into Q4 2027. The combination gives the company more room to decide how to develop or partner the asset, but it does not by itself establish a funded path through every stage of drug development.

The company's Q2 2026 earnings update included a stable $3.4 million net loss, the return of full GABAB PAM rights from Indivior and a $2.8 million fundraising, according to GuruFocus. The central business question is now how Addex will use the additional operating time and restored control.

Returned rights widen Addex's strategic choices

Regaining full rights changes who controls the program's commercial future. Addex can evaluate development priorities and potential licensing arrangements from the position of a rights holder, rather than depending on Indivior's continued involvement. That flexibility may matter when choosing which work to fund internally and which work could benefit from a partner.

GABAB refers to a receptor involved in nerve signaling. PAM stands for positive allosteric modulator, a compound designed to enhance a receptor's response through a separate binding site. The business significance here is the return of rights to that program, not a newly reported clinical result.

Control and funding are distinct advantages. Holding the rights gives Addex more authority over the asset, but development still requires resources, evidence and execution. A company can own a promising program without having the capital to pursue every possible application or complete all the work needed for commercialization.

The supplied update does not establish why the rights returned, disclose the contractual terms or identify a new development schedule. Investors therefore should not treat the transfer as proof of either scientific success or failure. Its demonstrated significance is that Addex has recovered full rights and can assess its next steps.

The financing buys operating time, not a finished program

The $2.8 million fundraising supports an operating runway into Q4 2027. A cash runway is the period a company expects its available resources to sustain its activities under its spending assumptions. It is a planning measure, rather than a guarantee that every contemplated project can be completed within that period.

For Addex, the financing and rights return are most useful when considered together. More operating time can help a rights holder evaluate development options, prepare work that supports a partnership discussion or negotiate without an immediate funding deadline. None of those possible uses has been established as Addex's chosen plan in the supplied facts.

The important limitation is scope. Funding operations into Q4 2027 does not necessarily mean funding the GABAB PAM program through a decisive clinical milestone. The update provides an operating horizon, but it does not specify which experiments, studies or regulatory activities that horizon includes.

That makes future spending priorities consequential. If Addex expands internally funded development, its resource needs could change. If it secures a partner that shares costs, it could pursue a different funding structure. These are alternative business paths, not announced transactions, and their implications depend on terms and commitments still to be disclosed.

A stable loss is not a cash-burn measure

Addex reported a stable $3.4 million net loss. Stability suggests the reported loss did not deteriorate on the comparison underlying the update, but the supplied facts do not identify that comparison or provide a detailed expense breakdown. They also do not establish whether spending on the returned program will change.

Net loss and cash consumption are not interchangeable. Accounting losses can include items that do not use cash during the reporting period, while cash movements can reflect payments and financing activity outside the income statement. The loss figure alone therefore cannot verify how long the fundraising will last.

It would be misleading to divide the $2.8 million raised by the $3.4 million loss and treat the result as a runway estimate. That calculation would substitute an accounting result for operating cash requirements and ignore other available resources. The relevant disclosed outlook is that operations are funded into Q4 2027.

The financial question for subsequent updates is whether actual spending remains consistent with that outlook. A clearer account of cash use and development commitments would help investors distinguish maintenance of existing operations from a broader investment in the newly controlled program.

Shares rise against a softer market

Addex shares were up 5.80% on the day as of the last trade at 16:29:32 GMT on October 1, 2026. The supplied quote recorded a price of 2.92, but did not identify its currency or listing exchange. Those details should not be assumed from the trading symbol.

The positive move contrasted with declines of 0.15% for the supplied S&P 500 benchmark, 0.18% for the Nasdaq 100 benchmark and 0.20% for the Dow 30 benchmark at the same stated time. Addex was moving against the broader market direction in that intraday snapshot.

That divergence does not establish why investors bought the shares. The snapshot shows a favorable price move, not whether buyers placed more weight on the returned rights, the financing or the reported loss. Nor does an intraday gain demonstrate that the company has resolved its longer-term development and funding risks.

The next test is a defined development plan

The most useful next disclosure would connect ownership, spending and milestones. Investors need to know what Addex intends to do with the GABAB PAM rights, which activities it can support with current resources and whether a new partner is part of the strategy.

Any future agreement would need to be assessed on more than its headline value. Responsibility for development costs, retained rights and conditions attached to payments would determine how much practical financial support it provides. For now, Addex has regained an asset and secured operating time; turning those advantages into a defined development path remains the task.

Key facts

• Net loss: Stable $3.4 million net loss in the Q2 2026 update.
• Program rights: Full GABAB PAM rights regained from Indivior.
• Financing and runway: $2.8 million raised to fund operations into Q4 2027.
• ADXN live quote: 2.92 (currency and exchange unspecified), up 5.80%; last trade October 1, 2026, at 16:29:32 GMT.

Frequently asked questions

What did Addex report in its Q2 2026 update?

Addex Therapeutics reported a stable $3.4 million net loss, regained full GABAB PAM rights from Indivior and raised $2.8 million to fund operations into Q4 2027. The update establishes a change in program control and an operating funding horizon, but does not supply a new clinical development schedule.

Why does regaining the GABAB PAM rights matter?

Full rights give Addex greater control over the program's development and potential licensing strategy. The company can evaluate internal investment or future partnerships as the rights holder. However, ownership does not establish clinical effectiveness, explain why the rights returned or demonstrate that all future development costs are funded.

What does the Q4 2027 cash runway mean?

Addex's funding outlook indicates that operations are supported into Q4 2027 under the assumptions behind that outlook. It should not be read as a promise that the GABAB PAM program will reach a particular clinical or regulatory milestone. The supplied facts do not identify which development activities the runway covers.

Can the $3.4 million net loss be used to calculate cash runway?

Not reliably from the supplied information. Net loss is an accounting measure and can differ from operating cash consumption. A sound runway assessment also requires available cash, expected spending and other commitments. Addex's disclosed outlook is funding into Q4 2027; the reported loss alone cannot independently verify that timeline.

How were Addex shares trading after the update?

ADXN was up 5.80% on the day at its last trade on October 1, 2026, at 16:29:32 GMT. The supplied price was 2.92, with currency and exchange unspecified. The major supplied benchmarks were lower, but that snapshot does not establish which part of Addex's update drove buying.

What should investors watch next at Addex?

The key next disclosures are Addex's development priorities for the returned GABAB PAM program, the spending required and whether it seeks a partner. Investors should also watch whether cash use remains consistent with the Q4 2027 operating outlook. Any future licensing agreement would need scrutiny of cost-sharing, retained rights and payment conditions.

Sources

• Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ... — GuruFocus

Photo: Belova59 · Pixabay Content License — source